Biomarker-Driven NSCLC Care: The Precision Medicine Model for Today and the Future

Pre-registration is now closed. We welcome you to register on-site by coming to the Sheraton New Orleans, 500 Canal Street, Grand Ballroom. Remember to bring your AACR badge to expedite your registration.


Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. Additionally, in accordance with AACR’s COVID-19 protocols, all in-person learners will be asked to wear a mask and present their AACR conference badge -OR- proof of vaccination AND Government-issued ID to gain admittance to Biomarker-Driven NSCLC Care: The Precision Medicine Model for Today and the Future. 

For more information on AACR’s vaccination and mask requirements, please visit: AACR’s website.

*If you do not have your vaccination record card, find out other ways to verify you have been vaccinated.

This symposium is sponsored by Clinical Care Options, LLC and supported by grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Lilly, Novartis Pharmaceuticals Corporation and Turning Point Therapeutics Inc. This is not an official program of the American Association for Cancer Research Annual Meeting.


Welcome and Introduction

Importance of Molecular Testing in NSCLC

Treatment Options for The Most Common Targetable Biomarkers for Advanced NSCLC: EGFR and KRAS 

Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: ALK, ROS, RET, TRK, MET

Practical Considerations: Putting It All Together

Final Thoughts


Presentations will include clinical cases and panel discussions, with time for questions from the audience.


Date / Time
Event Details


Program Director
Sandip P. Patel, MD

Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Todd M. Bauer, MD

Senior Investigator, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Joshua Sabari, MD

Assistant Professor of Medicine
Division of Thoracic Medical Oncology
Department of Medical Oncology
NYU Langone Health Perlmutter Cancer Center
Attending Physician, Thoracic Medical Oncology
Department of Medicine
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to optimally assess biomarkers and then effectively and safely integrate novels agents into their practice for patients with NSCLC.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess new and emerging predictive biomarkers to guide treatment decisions for individual patients with all stages of NSCLC
  • Plan therapeutic strategies for patients with NSCLC based on available evidence, tumor molecular profile, comorbidities, and expert recommendations
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, along with racial, age, and socioeconomic disparities
  • Identify existing disparities in care and barriers to biomarker testing and clinical trial enrollment for all patients with NSCLC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.